iPierian, a San Francisco-based biopharmaceutical company, has appointed Matthew Plunkett, PhD, as vice president and chief financial officer (CFO).
Previously, Plunkett spent nine years at Oppenheimer & Co, most recently as managing director where he lead the firm’s biotechnology investment banking practice for the West Coast. His investment banking experience includes over 60 completed biopharmaceutical transactions, including initial public offerings (IPOs), follow-on offerings, convertible debt, private placements, merger and acquisition (M&A) and financial advisory assignments. Prior to this, he worked as a research scientist at Sunesis Pharmaceuticals and at Axys Advanced Technologies.
Plunkett received a PhD in Organic Chemistry from the University of California, Berkeley.
A report by broking group Marsh examines the repercussions from the administration of the South Korean company, which filed for bankruptcy protection at the end of August.
Global research by C2FO suggests that smaller businesses are less concerned with the repercussions of Brexit and the upcoming US presidential election.
A squeeze on skilled talent means it now takes an average of seven weeks to fill open permanent roles in finance in the UK according to new research from financial services recruitment firm Robert Half.
Early-stage merger and acquisition deals in Asia-Pacific show nearly 10% year-on-year growth in recent months.